Physician profile
Alan Hussein
NPI 1306386339
$7,737.66
in general payments reported to CMS, 2019-2025
48 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,802 · 2022: $1,801 · 2023: $553 · 2024: $1,090 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,615.49 | 2021-2025 | |
| Novo Nordisk INC | $996.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $788.33 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $449.58 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $387.17 | 2021-2022 | |
| Pfizer INC. | $356.44 | 2021-2025 | |
| Lilly USA, LLC | $338.25 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $249.23 | 2024-2025 | Cologuard Collection Kit |
| Ucb, INC. | $234.40 | 2021-2022 | |
| Amarin Pharma, INC. | $202.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.00 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $176.13 | 2021-2022 | |
| Amgen INC. | $140.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.59 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.01 | 2024-2025 | Caplyta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.